https://www.selleckchem.com/pr....oducts/cathepsin-g-i
We tested in two groups all patients (n = 476, Model 1) and all patients with nonprimary brain cancers (n = 454, Model 2). In models 1 and 2, GDF-15 ≥2,290.9 pg/mL had adjusted ORs for VTE of 1.65 (95% confidence interval [CI] 0.89-3.08), and 2.28 (95% CI 1.28-4.09), respectively. hs-TnT ≥14.0 pg/mL was associated with higher odds of VTE in models 1 and 2 (adjusted ORs 2.26 [95% CI 1.40-3.65] and 2.03 [95% CI 1.07-3.84], respectively). For NT-proBNP, levels ≥183.5 pg/mL were not associated with VTE. Similar results were
Curtir
Comentario
Compartilhar
